#AANAM – Nuplazid Not Linked to Side Effects Common to Antipsychotics

#AANAM – Nuplazid Not Linked to Side Effects Common to Antipsychotics

293212

#AANAM – Nuplazid Not Linked to Side Effects Common to Antipsychotics

Acadia Pharmaceuticals’ Nuplazid (pimavanserin) — which is being evaluated as a potential treatment for hallucinations and delusions associated with dementia-related psychosis — is not associated with common motor side effects of conventional antipsychotics, according to an analysis of data from three clinical trials. These findings add to previous Phase 3 trial results showing that the therapy significantly lowered the risk of psychosis relapse — a worsening of hallucinations and delusions — in a wide range…

You must be logged in to read/download the full post.